Glycogen storage disease type Ia (GSD-Ia) is caused by a deficiency in glucose-6-phosphatase-a (G6Pase-a), a ninetransmembrane domain, endoplasmic reticulum-associated protein expressed primarily in the liver and kidney. Previously, we showed that infusion of an adeno-associated virus (AAV) serotype 2 vector carrying murine G6Pase-a (AAV2-G6Pase-a) into neonatal GSD-Ia mice failed to sustain their life beyond weaning. We now show that neonatal infusion of GSD-Ia mice with an AAV serotype 1-G6Pase-a (AAV1-G6Pase-a) or AAV serotype 8-G6Pase-a (AAV8-G6Pase-a) results in hepatic expression of the G6Pase-a transgene and markedly improves the survival of the mice. However, only AAV1-G6Pase-a can achieve significant renal transgene expression. A more effective strategy, in which a neonatal AAV1-G6Pase-a infusion is followed by a second infusion at age 1 week, provides sustained expression of a complete, functional, G6Pase-a system in both the liver and kidney and corrects the metabolic abnormalities in GSD-Ia mice for the 57 week length of the study. This effective use of gene therapy to correct metabolic imbalances and disease progression in GSD-Ia mice holds promise for the future of gene therapy in humans. Gene Therapy (2005) 13, 321-329.
Introduction
Glycogen storage disease type Ia (GSD-Ia), characterized by growth retardation, hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia, and lactic acidemia, is caused by a deficiency in glucose-6-phosphatase-a (G6Pase-a or G6PC), a key enzyme in glucose homeostasis. 1, 2 Over the last 25 years, dietary therapy consisting of nocturnal nasogastric infusion of glucose 3 or frequent oral administration of uncooked cornstarch 4 has significantly alleviated the metabolic abnormalities of GSD-Ia and greatly improved the prognosis. However, the underlying disease remains untreated and patients continue to suffer from hyperlipidemia, hyperuricemia, hypercalciuria, hypocitraturia, and lactic acidemia. As a result, long-term complications including kidney diseases and hepatocellular adenoma with malignant potential occur even in metabolically compensated GSD-Ia patients. 1, 2 G6Pase-a is a highly hydrophobic glycoprotein 5, 6 that is expressed primarily in the liver, kidney, and intestine. 7, 8 It contains nine transmembrane domains that anchor it in the endoplasmic reticulum (ER) membrane. 9 G6Pase-a catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose in the terminal step of glycogenolysis and gluconeogenesis. 8 Both pathways occur predominantly in the cytoplasm, but the active site of G6Pase-a resides within the lumen of the ER. 9, 10 Therefore, G6P hydrolysis is dependent upon transport of the cytoplasmic G6P across the ER membrane by a G6P transporter (G6PT). 1, 2, 11 To be functional, both G6Pase-a and G6PT must be coexpressed and embedded correctly in the ER membrane. 12 While protein replacement therapy is not an option, somatic gene therapy, targeting G6Pase-a to the liver and the kidney, is an attractive possibility.
To develop novel therapies for GSD-Ia, we had previously generated G6Pase-a-deficient (G6Pase-a À/À ) mice that manifest all of the symptoms of human GSD-Ia with the exception of hyperlactacidemia. 13 If left untreated, the mice rarely survive weaning and live no more than 3 months, mimicking the lethality of the untreated human disorder. Using these mice, we investigated the effects of viral-mediated G6Pase-a gene transfer in vivo. Two viral vectors were examined, adenovirus (Ad) and adeno-associated virus serotype 2 (AAV2). Recombinant Ad (rAd) vector-mediated G6Pase-a delivery gives a rapid, high-level expression of the transgene that can correct the deficiency, but the benefit is short-lived because of the rapid loss of vectormediated gene expression. 14 On the other hand, neonatal infusion of AAV2 carrying G6Pase-a (AAV2-G6Pase-a) alone fails to normalize hypoglycemia or sustain the life of G6Pase-a À/À mice 15 because the initial expression is too low. 16 This led us to demonstrate that a combined approach, in which a neonatal Ad-G6Pase-a infusion is combined with AAV2-G6Pase-a, could provide for both the short-and long-term expression needs. This strategy sustained G6Pase-a expression in both the liver and the kidney, and corrected the metabolic abnormalities of the GSD-Ia mice. 15 This is a promising start. While AAV2 is not considered pathogenic and has not been implicated in known human diseases, [17] [18] [19] rAd-mediated gene transfer is associated with inflammation and cellular immune responses. 20, 21 We, therefore, sought an improved strategy to avoid these complications.
Recently a number of new AAV serotypes have been identified. [22] [23] [24] These are gaining popularity not only because of their increased transduction efficiency but also because they circumvent the pre-existing immunity to the most common AAV2 serotype that is prevalent in over 70% of humans. In this study, we show that neonatal infusion of G6Pase-a À/À mice with either a rAAV serotype 1 vector carrying G6Pase-a (AAV1-G6Pase-a) or a rAAV serotype 8 vector carrying G6Pase-a (AAV8-G6Pase-a) effectively delivers the G6Pase-a transgene to the liver and markedly improves the survival of the mice. However, only AAV1-G6Pase-a delivers the transgene to both the liver and the kidney producing a functional G6Pase-a complex in both organs that normalizes metabolic abnormalities and achieves longterm correction of the GSD-Ia disorder in mice.
Results
Neonatal AAV8-G6Pase-a infusion directs hepatic G6Pase-a expression
In a previous study, 15 we showed that glucose therapy sustains the life of o15% of G6Pase-a À/À mice much beyond weaning (21-day) and even these mice continue to suffer from frequent hypoglycemic seizures, with few living to 3 months of age. Further, we showed that neonatal infusion of AAV2-G6Pase-a fails to improve the life of the G6Pase-a À/À mice beyond weaning. This failure is most likely due to the delayed kinetics of rAAV2-mediated transgene expression, which typically peaks 5-7 weeks postinfusion. 16 Since rAAV8 is reported to direct more efficient hepatic gene transfer, 16, 23 we examined whether neonatal AAV8-G6Pase-a infusion could improve the survival of the G6Pase-a À/À mice. We chose to express the G6Pase-a gene in AAV8-G6Pase-a driven by the hybrid CMV enhancer and chicken b-actin promoter to give broad tissue specificity since both liver and kidney G6Pase-a expression is required to correct the GSD-Ia disorder.
Neonatal G6Pase-a À/À mice were infused with 5 Â 10 11 particles of AAV8-G6Pase-a via the temporal vein. All three infused animals survived weaning. However, when expression of the G6Pase-a transgene was evaluated in the liver and the kidney at 4 weeks postinfusion, G6Pase enzymatic activity was detectable only in the liver.
There was no detectable expression in the kidney (data not shown). Since the volume of the virus that can be administered to a neonatal mouse is restricted by the size of the mouse, we sought to increase the viral dose by infusing the G6Pase-a À/À mice with two temporally separated doses -one in the neonatal period and a second when the animals reached age 1-week. Again, all three infused mice survived weaning. At 6 weeks postinfusion, the G6Pase-a activity in the liver and the kidney of the infused animals was examined and compared to that of age-matched G6Pase-a +/+ /G6Pase-a +/À littermates, and G6Pase-a À/À mice ( Table 1) . As expected, the G6Pase-a +/+ /G6Pase-a +/À littermates had G6Pase-a activity in both the liver and kidney, and the G6Pase-a À/À mice, supported only by glucose therapy, had no G6Pase-a activity. The AAV8-G6Pase-a-infused mice had 20.3% of normal hepatic G6Pase-a activity, but only 0.3% of normal kidney activity (Table 1) .
Neonatal AAV1-G6Pase-a infusion leads to hepatic and renal G6Pase-a expression A second new AAV-serotype reported to transduce liver efficiently is AAV1. 25, 26 For comparison to the rAAV8 results, we also placed the G6Pase-a gene in AAV1-G6Pase-a under the chicken b-actin promoter/CMV enhancer. In all, 12 G6Pase-a À/À mice were infused neonatally with 5 Â 10 11 particles of AAV1-G6Pase-a (AAV1-G6Pase-a-1X). All survived weaning. Five of these mice were killed for early expression analysis at 3 and 6 weeks of age (Table 2) . Of the remainder, three mice were sacrificed deliberately at 17, 26, and 48 weeks, and four mice died prematurely at 12, 13, 15, and 30 weeks postinfusion.
A key finding was that AAV1-G6Pase-a delivered a functional G6Pase-a transgene to both the liver and the kidney ( Table 2) . At 3 and 6 weeks postinfusion G6Pase-a activities in the liver and the kidney were B4 and B3% À/À mice that have been infused twice with AAV8-G6Pase-a. The unpaired t-test was used to evaluate the statistical difference in G6Pase-a activities in the liver and the kidney between infused and untreated G6Pase-a À/À mice. For G6Pase-a activity in the liver of the infused animals Po0.0001, and for G6Pase-a activity in the kidney of the infused animals P ¼ 0.48.
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A Ghosh et al of normal activity, respectively ( Table 2 ), indicating that B4% of hepatic G6Pase-a activity is sufficient to sustain the GSD-Ia mice beyond weaning. The respective activities persisted in both organs in the three treated mice that lived to 17, 26, and 48 weeks ( Table 2 ). Since four out of the seven AAV1-G6Pase-a-1X-infused mice died prematurely, the results suggest that these levels of hepatic and renal G6Pase activities are borderline for the survival of the treated G6Pase-a À/À mice.
Two AAV1-G6Pase-a-infusion prevent premature death of G6Pase-a À/À mice If a single infusion is borderline for survival, an increased dose of the transgene might be more successful. Given the size-related restriction to the volume of the first dose, we examined if a second dose of AAV1-G6Pase-a, delivered at 1 week of age, when all the mice are still thriving, could increase G6Pase-a transgene delivery and survival. Using this strategy, on nine animals, there were no premature deaths of AAV1-G6Pase-a-2X-infused G6Pase-a À/À mice prior to their deliberate sacrifices at 24 (n ¼ 3), 32 (n ¼ 2), and 49-57 (n ¼ 4) weeks postinfusion (Table 3) , significantly beyond the time of the previously observed premature deaths.
At 24 weeks postinfusion, G6Pase-a activities in the liver and the kidney of AAV1-G6Pase-a-2X-infused
G6Pase
À/À mice were B10 and B7% of normal activity, respectively (Table 3) , which were more than double the respective activities in AAV1-G6Pase-a-1X-infused animals (compare Tables 2 and 3 ). The high levels of hepatic and renal G6Pase activity persisted in the infused animals for the duration of the 57-week study (Table 3) . The results indicate that B11% of normal hepatic activity and B7% of normal renal G6Pase activity are adequate to sustain the G6Pase-a À/À mice for at least 57 weeks. Effective G6Pase activity in vivo is dependent upon coupling of the G6Pase-a enzyme to the membrane anchored G6PT, [11] [12] [13] which translocates G6P from the cytoplasm into the lumen of the ER for hydrolysis. In G6Pase-a À/À mice, the transport of G6P into the hepatic and renal microsomes is markedly reduced. 13 We therefore looked at the effect of the transgene expression on microsomal G6P uptake activity in the liver and the kidney of the AAV1-G6Pase-a-2X-infused animals. Both the liver and kidney microsomes from G6Pase-a +/+ / G6Pase-a +/À mice transport G6P efficiently and there is no significant G6P uptake by the liver or kidney microsomes of the untreated G6Pase-a À/À mice ( Table  3 ). In the AAV1-G6Pase-a-2X-infused G6Pase-a À/À animals, microsomal G6P uptake activity was restored between 28 and 33% of normal levels in the liver and between 43 and 53% of normal levels in the kidney (Table 3) . Table 2 Heptic and renal G6Pase activities in G6Pase-a À/À mice after a single neonatal AAV1-G6Pase-a infusion Mice Postinfusion (weeks) Liver G6Pase activity (nmol/min/mg) Kidney G6Pase activity (nmol/min/mg)
G6Pase-a À/À (À/À) mice were infused once (1X) neonatally with AAV1-G6Pase-a as described under Materials and methods. Age-matched G6Pase-a +/+ /G6Pase-a +/À (+/+ & +/À) mice were used as positive controls. G6Pase-a À/À mice at 4-6 weeks of age were used as negative controls. Values in the table have been corrected for background by subtracting the G6Pase activity (nmol/min/mg) in the liver (2.870.3) or the kidney (4.070.6) microsomes of untreated G6Pase-a À/À mice from the respective results. Data are presented as mean7s.e.m. Numbers in parentheses represent percent of G6Pase-a +/+ /G6Pase-a +/À activity. AAV1-G6Pase-a-1X denotes G6Pase-a À/À mice that have been infused once with AAV1-G6Pase-a. The unpaired t-test was used to evaluate the statistical difference in G6Pase-a activities in the liver and the kidney between infused and untreated G6Pase-a À/À mice. Po0.001 for all hepatic activity comparisons, and Po0.01 for all renal activity comparisons. G6Pase-a À/À (À/À) mice were infused with two doses (2X) of AAV1-G6Pase-a once in the neonatal period and once when they reached age 1-week as described under Materials and methods. Age-matched G6Pase-a +/+ /G6Pase-a +/À (+/+ & +/À) mice were used as positive controls. G6Pase-a À/À mice at 4-6 weeks of age were used as negative controls. Values in the table have been corrected for background by subtracting the G6Pase activity (nmol/min/mg) in the liver (2.870.6) or the kidney (4.270.6) microsomes as well as the G6P uptake activity (nmol/mg/ 3 min) in the liver (0.02370.004) or the kidney (0.02170.002) microsomes of untreated G6Pase-a À/À mice from the respective results. Data are presented as mean7s.e.m. Numbers in parentheses represent percent of G6Pase-a +/+ /G6Pase-a +/À activity. AAV1-G6Pase-a-2X denotes G6Pase-a À/À mice that have been infused twice with AAV1-G6Pase-a. The unpaired t-test was used to evaluate the statistical difference in G6Pase-a and G6P uptake activities in the liver and the kidney between infused and untreated G6Pase-a À/À mice. Po0.001 for all comparisons.
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The distribution of the G6Pase-a transgene expression in the liver and kidney was also investigated. In G6Pase-a +/+ /G6Pase-a +/À mice, G6Pase-a is distributed uniformly throughout hepatocytes, but more localized in the kidney, predominantly being expressed in the cortex. 7, 15 This pattern of expression was confirmed by enzyme histochemical analyses ( Figure 1 ). As expected, there was no stainable G6Pase-a activity in liver or kidney sections of untreated G6Pase-a À/À mice. For the AAV1-G6Pase-a-2X-infused G6Pase-a À/À mice the entire liver and kidney stained positive at 49 or 57 weeks postinfusion and there was no evidence for preferred expression in the kidney cortex (Figure 1) . Consistent with the quantitative phosphohydrolase assays (Table 3) , the staining was less intense than that of the G6Pase-a +/+ mice. This indicates that the rAAV1 delivers the G6Pase-a transgene to the entire liver and kidney, and that noncortical areas of the kidney are contributing to the total phosphohydrolase activities being measured.
G6Pase-a À/À mice under glucose therapy are growth retarded and by 2 weeks old their average body weight is approximately 60% of their wild-type or heterozygous littermates.
14 After two AAV1-G6Pase-a infusions, the G6Pase-a À/À mice have a markedly improved growth rate and the body weights of the infused animals are comparable to those of G6Pase-a +/+ /G6Pase-a +/À littermates at 4 weeks postinfusion (Figure 2a) . The comparable growth rate was maintained for the duration of the 57-week study.
AAV1-G6Pase-a-2X infusion corrects pathological manifestations of GSD-Ia
Under glucose therapy, G6Pase-a À/À mice manifest hypoglycemia, hypercholesterolemia, hypertriglyceridemia, and hyperuricemia. 13 Although AAV1-G6Pase-a-2X-infused G6Pase-a À/À mice were hypoglycermic at 2 weeks of age, their serum glucose profiles were normalized soon after, and this normoglycemia was maintained throughout their postnatal development (Figure 2b) . None of the mice suffered the frequent hypoglycemic seizures typical of the untreated G6Pase-a À/À mice. Moreover, like G6Pase-a +/+ /G6Pase-a +/À mice, the AAV1-G6Pase-a-2X infused G6Pase-a À/À mice maintained normoglycemia, even when deliberately starved for 2 h. While the AAV1-G6Pase-a-2X-infused animals manifested hypercholesterolemia, hypertriglyceridemia, and hyperuricemia at 2 weeks of age, their serum cholesterol, triglyceride, and uric acid profiles were completely normal by age 4 weeks, and this normality persisted for the duration of the 57-week study (Figure 2b) .
Hepatomegaly is another clinical presentation in GSD-Ia mice, which results from excessive glycogen accumulation in the liver.
1,2 As expected, the liver weights of 4-6-week-old G6Pase-a À/À mice were markedly elevated reaching 9-18% of body weight (data not shown), compared to the wild-type values of 4%. As only a few G6Pase-a À/À mice lived to 12 weeks of age, we compared the liver weights of AAV1-G6Pase-a-2X-infused animals to that of G6Pase-a +/+ /G6Pase-a +/À mice and AAV1-G6Pase-a-1X-infused animals. Hepatomegaly was markedly improved after AAV1-G6Pase-a-2X infusion and the average relative liver weight in AAV1-G6Pase-a-2X-infused animals was 6.370.5% of body weight lying mid-way between the normal range of to 4.170.2% for G6Pase-a +/+ /G6Pase-a +/À mice and the higher range of 9.870.8% for AAV1-G6Pase-a-1X-infused animals (Figure 2c ). Hepatomegaly in GSD-Ia is primarily caused by glycogen deposition and hepatic glycogen content in AAV1-G6Pase-a-2X-infused animals was 400.8716.7 mmol glucosyl residues per gram liver wet weight. This lies mid-way between the normal range of 224.4721.1 for the control littermates and the higher range of 815.5748.4 for AAV1-G6Pase-a-1X-infused animals. Throughout postnatal development, the transduced liver tissue sections from AAV1-G6Pase-a-2X-infused animals showed no histological abnormality, Figure 1 Histochemical analysis of G6Pase-a activity in the liver and kidney of AAV1-G6Pase-a-2X-infused G6Pase-a À/À mice. Freshly sectioned liver and kidney specimens from untreated G6Pase-a À/À (À/À), AAV1-G6Pase-a-2X-infused G6Pase-a À/À (À/À AAV1-G6Pase-a), and G6Pase-a +/+ (+/+) mice were analyzed for G6Pase activity using the method of lead trapping of phosphate generated by G6P hydrolysis 40 at a magnification of Â 100. The kidney cortex is denoted by an arrow.
rAAV1-mediated gene therapy for GSD-Ia A Ghosh et al except for a mild glycogen accumulation ( Figure 3) . The results suggest that B11% of normal hepatic G6Pase-a activity (Table 3) is sufficient to maintain close to normal liver functions. Nephromegaly is also a clinical manifestation of human and mouse GSD-Ia. 1, 2 As expected, glycogen storage in the kidney of G6Pase-a +/+ /G6Pase-a +/À mice is low with an average relative kidney weight of 1.2570.05% of body weight (Figure 2c) . In AAV1-G6Pase-a-2X-infused mice the relative kidney weight increased almost three-fold, reaching 3.770.3%, but was still below the 4.870.8% of body weight observed for the AAV1-G6Pase-a-1X-infused mice (Figure 2c ). Despite the increased glycogen deposition in the transduced kidney tissues at 32 weeks post-AAV1-G6Pase-a-2X-infusion, histological abnormalities were not observed (Figure 3) . However, variable degrees of histological abnormalities were observed in the transduced kidney tissues at 49-57 weeks postinfusion. While the kidney tissues of one animal at 49 week showed little or no histology abnormalities, the other three infused animals at age 49, 49, and 57 weeks exhibited histological abnormalities including glomerular sclerosis as shown in the kidney tissues of the mouse at 57-week postinfusion (Figure 3) . Serum creatinine, an index of altered renal function, 27 was then examined. The creatinine levels in the serum of 49-57-week-old G6Pase-a +/+ /G6Pase-a +/À mice were 0.2570.04 mg/dl (Figure 4a ). Serum creatinine levels in the four AAV1-G6Pase-a-2X-infused animals that lived to 49-57 weeks of age remained normal at 0.1970.02 mg/dl. In contrast, serum creatinine levels in 4-to 6-week-old control G6Pase-a À/À mice were markedly increased reaching 2.5770.18 mg/dl (Figure 4a ).
Absence of immune response against murine G6Pase-a
To determine whether a humoral response directed against murine G6Pase-a is generated in the infused G6Pase-a À/À mice, we performed Western blot analysis using sera from mice infused twice with AAV1-G6Pase-a. As a positive control, we used a rabbit anti-G6Pase-a antiserum. 10 Results in Figure 4b showed that no antiG6Pase-a antibodies were detected in any of the AAV1-G6Pase-a-2X-infused G6Pase-a À/À mice that lived to age 49-57 weeks. Furthermore, there was no endogenous anti-G6Pase-a antibody present in the sera of G6Pase-a +/+ / G6Pase-a +/À littermates (lanes 3, 6, 9, 12) or untreated G6Pase-a À/À mice (lane 2).
Discussion
G6Pase-a is a highly hydrophobic, multiple domain, transmembrane ER protein 9 expressed primarily in the rAAV1-mediated gene therapy for GSD-Ia A Ghosh et al liver and kidney. 7, 8 This phosphatase cannot be expressed in a soluble form and to be functional, must embed correctly in the ER membrane and couple with the G6PT. 1,2,11 Therefore, to correct the GSD-Ia disorder, a functional G6Pase-a complex must be restored in both the liver and the kidney. In this study, we have explored the efficacy of rAAV1 and rAAV8 mediated G6Pase-a gene delivery to the liver and kidney of G6Pase-a À/À mice. The G6Pase-a gene in both recombinants is driven by the hybrid chicken b-actin promoter/CMV enhancer. When equivalent physical doses of AAV1-G6Pase-a and AAV8-G6Pase-a are given, they both direct efficient hepatic G6Pase-a expression, although AAV8-G6Pase-a directs almost twice the level of transgene expression than AAV1-G6Pase-a. In contrast, only AAV1-G6Pase-a can direct kidney expression of the transgene. Further, increasing the AAV1 gene dosage by two temporally separated infusions, one into the neonate at 1-2 days of age and the second at 1 week of age, elevates the sustained level of expression of the transgene in both the liver and kidney, over a single dose, preventing premature deaths and resulting in a long-term, functional correction of the murine GSD-Ia disorder. The doubly infused animals grow normally, exhibit normal serum glucose, cholesterol, triglyceride, and uric acid profiles, and suffer no premature death throughout the 57-week study. They do show an elevation in liver and kidney weights relative to body weight, although the serum creatinine levels remain within the normal range.
Both AAV1 and AAV8 are pseudotyped AAV vectors containing the AAV2 inverted terminal repeats that are required for AAV replication, rescue, packaging, and integration. [22] [23] [24] Studies have shown that the capsid gene of the AAV determines the properties of the viral particles including their tissue tropism and antigenic properties. 28 The different efficiencies in transducing the Figure 3 Histological analysis of the liver and kidney from the AAV1-G6Pase-a-2X infused G6Pase-a À/À mice. Plates show hematoxylineosin stained liver and kidney sections from G6Pase-a +/+ (+/+), AAV1-G6Pase-a-2X-infused G6Pase-a À/À (À/ÀAAV1-G6Pase-a), and untreated G6Pase-a À/À (À/À) mice at magnifications of Â 200. Note the abnormalities including glomerular sclerosis (indicated by an arrow) in the kidney of G6Pase-a À/À mice at 57 weeks post-AAV1-G6Pase-a-2X-infusion. rAAV1-mediated gene therapy for GSD-Ia A Ghosh et al liver and kidney between rAAV1 and rAAV8 seen in this study probably reflect the differences in the capsid gene products and their counterpart receptors on the tissue surfaces of the liver and kidney. The sustained hepatic and renal G6Pase-a expression mediated by AAV1-G6Pase-a persists over 57 weeks with no apparent decline. This is in contrast to our previous study in which we showed a partially successful gene therapy strategy using a coinfusion of Ad-G6Pase-a and AAV2-G6Pase-a. 15 In those studies, hepatic and renal G6Pase-a transgene expression persisted over 34 weeks. However, G6Pase activity in the liver declined 28% and kidney activity declined 60%, by 52 weeks postinfusion as compared to the activities at 34 weeks postinfusion. 15 These declines were attributed to immune responses against the adenoviral proteins, the net result of which is the elimination of the transduced cells and hence the G6Pase-a transgene.
Although intravenous infusion of rAAV primarily directs liver transgene expression, 29, 30 other organs or tissues may express low levels of the transgene because the G6Pase-a gene in the recombinants is driven by the hybrid chicken b-actin promoter/CMV enhancer. This inappropriate, low-level G6Pase-a expression in organs or tissues outside the liver and kidney should pose no apparent adverse effect. We, and others, have recently reported the characterization of a ubiquitously expressed G6P hydrolase, G6Pase-b. 31, 32 G6Pase-b appears very similar to G6Pase-a in that it shares structural and kinetic similarities to G6Pase-a and couples with G6PT to form an active G6Pase-b complex. 31 However, the overall activity of G6Pase-b is only B12% that of G6Pase-a. So a low level of G6Pase activity is already widely expressed and we would expect the low level of cellinappropriate expression of recombinant G6Pase-a to be well tolerated. On the other hand, increased hepatic G6Pase-a activity has been found in human diabetes 33 and in experimental rodent diabetic models. 34, 35 Thus, constitutively high-level hepatic G6Pase-a expression may lead to the development of diabetes, and warrants further investigation.
In the livers of the AAV1-G6Pase-a-2X-infused animals there was no histological abnormality and all the mice had normal serum glucose, cholesterol, triglyceride, and uric acid profiles. Biochemical measurement of hepatic enzymatic activities from all treated mice show sustained restoration of approximately 4.5% of the normal hepatic G6Pase-a activity in the mice receiving a single infusion and 11% of the normal hepatic G6Pase-a activity in mice receiving a double infusion. Since several of the mice receiving a single infusion died prematurely, but no mice receiving a double infusion died over the course of a 57-week study, it suggests that the minimal liver activity required for the maintenance of glucose homeostasis, in mice, lies between 4.5 and 11% of the wild-type activity.
During the first 32 weeks post-AAV1-G6Pase-a-2X-infusion, renal G6Pase-a activity is restored to B7% of the wild-type level, which prevents the infused G6Pase-a À/À mice from developing renal lesions despite substantial glycogen deposition. Abnormal renal histology appeared in three of the four infused animals that were allowed to live beyond 49 weeks of age. In wild-type mice, G6Pase-a activity is restricted to the kidney cortex, but in AAV1-G6Pase-a-infused mice, the transgene is expressed uniformly throughout the kidney (Figure 1) . These results suggest that 7% of wild-type renal G6Pase-a activity, when uniformly expressed throughout the kidney tissues, cannot prevent longer-term kidney complications.
In the last two and half decades, dietary therapy has allowed GSD-Ia patients to maintain euglycemia and avoid the early symptomatic signs of the disease. However, patients continue to suffer from hyperlipidemia, hyperuricemia, hypercalciuria, hypocitraturia, and lactic acidemia, which facilitate the slow progression of kidney disease. 1, 2 This is typified by renal stones, nephrocalcinosis, nephrolithiasis, and progressive renal disease that become a frequent and life-threatening complication for older patients. The success of a kidney transduction by rAAV1 in mice offers hope that a similar strategy in humans might also prove of value in gene therapy of renal diseases.
In summary, using a murine model of GSD-Ia, we have demonstrated that an AAV1-G6Pase-a-mediated gene therapy delivers the G6Pase-a transgene to both the liver and kidney, resulting in the restoration of a sustained, functional G6Pase-a complex and the correction of the underlying metabolic disorder. Our results suggest that human GSD-Ia may be amenable to G6Pase-a gene therapy.
Materials and methods
Construction of AAV-G6Pase-a AAV1-G6Pase-a was packaged by cotransfection of 293 cells with three plasmids: UF11-G6Pase-a, a rAAV vector containing murine G6Pase-a driven by the chicken bactin promoter/CMV enhancer; 36 pDG 37 containing AAV2 rep and adenoviral helper genes; and a chimeric packaging plasmid pXYZ1 containing AAV1 cap.
38
AAV8-G6Pase-a was packaged by cotransfection of 293 cells with UF11-G6Pase-a; 80-XX6, an adenoviral helper plasmid; 39 and a chimeric packaging plasmid pAAV8-2.
23
The AAV1-G6Pase-a or AAV8-G6Pase-a virions were obtained by freeze-thaw lysis of the transfected cells and purified by iodixanol gradient ultracentrifugation followed by HiTrap Q column chromatography (Pharmacia, Piscataway, NJ, USA). The virus preparations were quantified by dot-blot for the physical titer. 40 Infusion of G6Pase-a À/À mice with AAV-G6Pase-a
All animal studies were conducted under an animal protocol approved by the NICHD Animal Care and Use Committee. A glucose therapy was administered to the G6Pase-a À/À mice as described previously 15 and mice that survived weaning were given unrestricted access to Mouse Chow (Zeigler Bros. Inc., Gardners, PA, USA). The volume of the virus that can be administered to a neonatal mouse is restricted by the size of the mouse. Therefore, we conducted two parallel studies. One group of mice was infused once neonatally, the second group was infused with two doses -once in the neonatal period and again when the animals reached age 1 week.
Neonatal (1-or 2-day-old) G6Pase-a À/À mice were infused via the temporal vein with 30 ml of recombinant viruses containing 5 Â 10 11 particles of AAV1-G6Pase-a or AAV8-G6Pase-a. A second infusion of 1.5 Â 10 12 particles of AAV1-G6Pase-a or AAV8-G6Pase-a was administered rAAV1-mediated gene therapy for GSD-Ia A Ghosh et al via the retro-orbital vein when the infused animals reached age 1-week. Age-matched G6Pase-a +/+ /G6Pase-a +/À as well as 4-6 week old G6Pase-a À/À mice were used as controls. For the virus-infused mice, glucose therapy was terminated immediately after infusion.
Phosphohydrolase and G6P uptake assays
Microsomal preparations and phosphohydrolase assays were performed as described previously. 13 Appropriate amounts of microsomal proteins were incubated at 301C for 10 min in reaction mixtures (100 ml) containing 50 mM sodium cacodylate buffer pH 6.5, 10 mM G6P, and 2 mM EDTA. Disrupted microsomal membranes were prepared by incubating intact membranes in 0.2% deoxycholate for 20 min at 01C. Enzyme histochemical analysis of G6Pase-a was performed by incubating 10 mm thick tissue sections for 10 min at room temperature in a solution containing 40 mM Tris-maleate pH 6.5, 10 mM G6P, 300 mM sucrose, and 3.6 mM lead nitrate. The trapped lead phosphate was visualized following conversion to the brown colored lead sulfide.
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G6P uptake measurements were performed as described. 13, 15 Briefly, microsomes were incubated in a reaction mixture (100 ml) containing 50 mM sodium cacodylate buffer pH 6.5, 250 mM sucrose, and 0.2 mM [U- C]glucose. Microsomes permeabilized with 0.2% deoxycholate, to abolish G6P uptake, were used as negative controls.
Phenotype analysis
Mouse blood samples were collected by orbital bleeding as previously described.
14 Serum glucose, triglycerides, total cholesterol, and uric acid levels were analyzed using kits obtained from Sigma Diagnostics and serum creatinine levels were analyzed using a kit obtained from Cayman Chemical (Ann Arbor, MI, USA). For hematoxylin and eosin staining, tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 4-6 mm-thickness. To determine the glycogen content of the liver, tissue was homogenized with HCl, boiled for 10 min, and neutralized with sodium acetate to a final pH of 4.5. 41 The hydrolyzed tissue was then digested with amylo-a-1,4-a-1,6-glucosidase 41 and the released glucose was measured using a kit obtained from Sigma Diagnostics. Glycogen content is reported as mmol glucosyl residues per gram wet weight of tissue.
Antibody assays
Antibodies against murine G6Pase-a were detected by Western-blot analysis. Microsomal proteins from AdG6Pase-a infected COS-1 cells 10 were resolved by electrophoresis through a 12% polyacrylamide-SDS gel and trans-blotted onto polyvinylidene fluoride membranes (Millipore Co., MA, USA). The membrane was placed in a Multiscreen Apparatus (Bio-Rad, CA, USA) containing multiple channels. The membrane strip under each channel was incubated with a rabbit anti-human G6Pase-a antiserum 10 diluted 1:3000, or serum samples from AAV1-G6Pase-a-infused animals diluted 1:200. Serum samples from untreated G6Pase-a À/À and G6Pase-a +/+ /G6Pase-a +/À littermates diluted 1:200 were used as controls. The antigen-antibody complex was visualized as described previously. 15 
